SAN DIEGO - illiNews -- Mapp Biopharmaceutical, Inc. (MappBio), announced today that it has been awarded an advanced research and development contract for $16.5 million with options for an additional $30.0 million by the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services (HHS) to advance MBP091 though the completion of a Phase 1 clinical trial.
MBP091 is a single human monoclonal antibody (mAb) that is being developed as a pan-Marburg virus therapeutic for the treatment of hemorrhagic fevers caused by Marburg and the closely related Ravn virus. The mAb was isolated in the laboratory of Dr. James Crowe at Vanderbilt University Medical Center from a survivor or Marburg virus infection and subsequently licensed by Mapp. MBP091 has been evaluated in numerous preclinical experiments and has demonstrated the ability to neutralize Marburg virus in vitro and protect from lethal challenge of Marburg in vivo.
Marburg virus is a member of the filovirus family and causes a hemorrhagic fever similar to that caused by Ebola. First identified in 1967, Marburg virus has caused numerous outbreaks, even as recently as 2017 in Uganda, with relatively high mortality rates. "The award of this contract by BARDA will allow Mapp to advance the development of MBP091 to first in human evaluation with the ultimate goal of making this medical countermeasure available to victims of Marburg virus," said Dr. Ronald Aimes, Vice President of Nonclinical Development at Mapp and the Principal Investigator on this contract.
More on illi News
"We are pleased to continue and expand our productive relationship with BARDA, which represents a good example of a public-private partnership that advances much needed therapeutics for infected individuals and the Strategic National Stockpile," said Dr. Kevin J. Whaley, Chief Executive Officer.
###
About Mapp Biopharmaceutical: Mapp Biopharmaceutical was founded in 2003 to develop novel pharmaceuticals for the prevention and treatment of infectious diseases, focusing on unmet needs in global health and biodefense. www.mappbio.com
This project has been funded in whole or in part with Federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority, under Contract Nos. HHSO100201900018C and HHSO100201700023C, a National Institute of Health grant No. 2SB1 AI082744 and Medical CBRN Defense Consortium Base Agreement 2018-843 under OTA W15QKN-16-9-1002.
MBP091 is a single human monoclonal antibody (mAb) that is being developed as a pan-Marburg virus therapeutic for the treatment of hemorrhagic fevers caused by Marburg and the closely related Ravn virus. The mAb was isolated in the laboratory of Dr. James Crowe at Vanderbilt University Medical Center from a survivor or Marburg virus infection and subsequently licensed by Mapp. MBP091 has been evaluated in numerous preclinical experiments and has demonstrated the ability to neutralize Marburg virus in vitro and protect from lethal challenge of Marburg in vivo.
Marburg virus is a member of the filovirus family and causes a hemorrhagic fever similar to that caused by Ebola. First identified in 1967, Marburg virus has caused numerous outbreaks, even as recently as 2017 in Uganda, with relatively high mortality rates. "The award of this contract by BARDA will allow Mapp to advance the development of MBP091 to first in human evaluation with the ultimate goal of making this medical countermeasure available to victims of Marburg virus," said Dr. Ronald Aimes, Vice President of Nonclinical Development at Mapp and the Principal Investigator on this contract.
More on illi News
- RedLine Athletics Announces the Grand Opening for its Keller, Texas Location
- Mayor Lightfoot, Chicago Public Schools, and The Department of Cultural Affairs and Special Events (DCASE) Celebrate Arts and Culture at Solorio Academy High School
- BOMANI Cold Buzz™ Announces Partnership with Integrity Wellness Brands
- Attorney Chase Howard Joins Florida Healthcare Law Firm
- National Event for Singles Launches
"We are pleased to continue and expand our productive relationship with BARDA, which represents a good example of a public-private partnership that advances much needed therapeutics for infected individuals and the Strategic National Stockpile," said Dr. Kevin J. Whaley, Chief Executive Officer.
###
About Mapp Biopharmaceutical: Mapp Biopharmaceutical was founded in 2003 to develop novel pharmaceuticals for the prevention and treatment of infectious diseases, focusing on unmet needs in global health and biodefense. www.mappbio.com
This project has been funded in whole or in part with Federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority, under Contract Nos. HHSO100201900018C and HHSO100201700023C, a National Institute of Health grant No. 2SB1 AI082744 and Medical CBRN Defense Consortium Base Agreement 2018-843 under OTA W15QKN-16-9-1002.
Source: Mapp Biopharmaceutical, Inc.
Filed Under: Government
0 Comments
Latest on illi News
- Autumn in Japan's Ashikaga & Tatebayashi Areas
- Covenant Living Communities And Services Purchases Continuing Care Retirement Community
- Arsenal Recon Releases Major Update to Powerful Digital Forensics Tool
- Intalytics Taps INRIX to Provide Retailers with Best-in-Class Traffic Data for Decision Analysis
- Registration Open: ACI's 10th Annual New York Economic Sanctions Forum Dec. 10-11 New York City
- Official Launch of ExhibitDay.com
- Former Samsung President and CEO Philip Sullivan Joins CEO Coaching International
- Trump Loving Life Coach's New Book Encourages Transparent, Well Intentioned Discussion To Bring Americans Closer
- Fairfield Gourmet Food Corporation - The Parent Company of David's Cookies Announces the Acquisition of Foxtail Foods
- Doosan Machine Tools Selects MachBase Time-Series Database for Enhanced Edge Computing Capabilities
- Bystronic Introduces ByStar Fiber Laser Cutter with 12kW Fiber Power
- Mobile Cannabis Lounge Tours Land in Los Angeles
- REV•1 Engineering® Takes Early Phase Medical Device Development To The Next Level
- Various Measures Introduced to and Approved by the Chicago City Council
- Eaton Hudson Contracted to Sell Fixed Assets Of Midstate College. Sale Starts October 1st
- Paul Romer, Nobel Prize Recipient for Economic Sciences, joins Worldwide Speakers Group
- Peerless-AV® Partners With BIMsmith® to Provide Digital Models for Building Professionals
- New World Record Efficiency with Flexible CIGS Solar Cell
- The Pet Gal Named One of Top Austin Area Women-Owned Businesses for 2018 Total Revenue
- Habitu8 Named Official Video Partner for National Cyber Security Awareness Month